Sarbani Chaudhuri - 11 Feb 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Chief Commercial & Medical Affairs Officer
Issuer ticker: RCKT
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:05:19 UTC
Prior SEC filing: 22 Apr 2025
Next SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Sarbani Chaudhuri

Key filing fact

Sarbani Chaudhuri filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 13 Feb 2026.

Key facts

This page summarizes Sarbani Chaudhuri's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 22 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002064940 Primary reporting owner

Chaudhuri Sarbani

Relationship: Chief Commercial & Medical Affairs Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Sarbani Chaudhuri
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value: $0
Shares: +125,924
Change %: +79%
Price: $0.000000
Shares after: 285,160
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +189,076
Change %
Price: $0.000000
Shares after: 189,076
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 189,076
Exercise price: $3.24
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Footnote F2

Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

Footnote F3

This option represents a right to purchase a total of 189,076 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

SEC remarks

Chief Commercial & Medical Affairs Officer